6
IRUS Total
Downloads
  Altmetric

Computational prediction of protein subdomain stability in MYBPC3 enables clinical risk stratification in hypertrophic cardiomyopathy and enhances variant interpretation

File Description SizeFormat 
s41436-021-01134-9.pdfPublished version798.77 kBAdobe PDFView/Open
Title: Computational prediction of protein subdomain stability in MYBPC3 enables clinical risk stratification in hypertrophic cardiomyopathy and enhances variant interpretation
Authors: Thompson, AD
Helms, AS
Kannan, A
Yob, J
Lakdawala, NK
Wittekind, SG
Pereira, AC
Jacoby, DL
Colan, SD
Ashley, EA
Saberi, S
Ware, JS
Ingles, J
Semsarian, C
Michels, M
Mazzarotto, F
Olivotto, I
Ho, CY
Day, SM
Item Type: Journal Article
Abstract: Purpose: Variants in MYBPC3 causing loss of function are the most common cause of hypertrophic cardiomyopathy (HCM). However, a substantial number of patients carry missense variants of uncertain significance (VUS) in MYBPC3. We hypothesize that a structural-based algorithm, STRUM, which estimates the effect of missense variants on protein folding, will identify a subgroup of HCM patients with a MYBPC3 VUS associated with increased clinical risk. Methods: Among 7,963 patients in the multicenter Sarcomeric Human Cardiomyopathy Registry (SHaRe), 120 unique missense VUS in MYBPC3 were identified. Variants were evaluated for their effect on subdomain folding and a stratified time-to-event analysis for an overall composite endpoint (first occurrence of ventricular arrhythmia, heart failure, all-cause mortality, atrial fibrillation, and stroke) was performed for patients with HCM and a MYBPC3 missense VUS. Results: We demonstrated that patients carrying a MYBPC3 VUS predicted to cause subdomain misfolding (STRUM+, ΔΔG ≤ −1.2 kcal/mol) exhibited a higher rate of adverse events compared with those with a STRUM- VUS (hazard ratio = 2.29, P = 0.0282). In silico saturation mutagenesis of MYBPC3 identified 4,943/23,427 (21%) missense variants that were predicted to cause subdomain misfolding. Conclusion: STRUM identifies patients with HCM and a MYBPC3 VUS who may be at higher clinical risk and provides supportive evidence for pathogenicity.
Issue Date: 1-Jul-2021
Date of Acceptance: 16-Feb-2021
URI: http://hdl.handle.net/10044/1/88170
DOI: 10.1038/s41436-021-01134-9
ISSN: 1098-3600
Publisher: American College of Medical Genetics and Genomics
Start Page: 1281
End Page: 1287
Journal / Book Title: Genetics in Medicine
Volume: 23
Copyright Statement: © The Author(s) 2021. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Sponsor/Funder: Wellcome Trust
British Heart Foundation
Funder's Grant Number: 107469/Z/15/Z
RE/18/4/34215
Keywords: Science & Technology
Life Sciences & Biomedicine
Genetics & Heredity
Science & Technology
Life Sciences & Biomedicine
Genetics & Heredity
0604 Genetics
1103 Clinical Sciences
Genetics & Heredity
Publication Status: Published
Open Access location: https://www.nature.com/articles/s41436-021-01134-9
Online Publication Date: 2021-03-29
Appears in Collections:National Heart and Lung Institute
Institute of Clinical Sciences
Faculty of Medicine



This item is licensed under a Creative Commons License Creative Commons